Page 153 - CW E-Magazine (8-4-2025)

Pharmaceuticals

FINANCIAL TROUBLES
Sun Pharma says US-based Lyndra Therapeutics

ceasing operations due to “insuffi cient funding”

The Massachusetts-based Lyndra available on the existing tie-up, in the or longer in an oral dosage form. Based
Therapeutics Inc. “is ceasing opera- light of Lyndra’s announcement. on technology invented in the Langer
tions from March 26th, due to insuffi - Lab at MIT, the LYNX platform has
cient funding to continue their business The acquisition was meant to be a progressed rapidly since 2015 through
activities,” said Sun Pharmaceutical strategic investment to support the deve- preclinical and early human studies and
Industries, who is invested in the US lopment of innovative pharmaceutical achieved proof of concept of the plat-
company. delivery technologies and get access form and lead asset in a Phase-2 study,
to the technology for certain molecules it had said.
In December 2023, Sun Pharma and territories, Sun had then said.
had invested in Lyndra Therapeutics – Lyndra was incorporated on January
agreeing to acquire about 16.7 percent In July 2023, Lyndra had said its 14, 2015 and its revenues over the
in the company, engaged in developing trademarked Lyndra’s LYNX drug last three years, (January-December),
novel delivery technology for long- delivery platform was a significant have been reducing from $25.6-mn
acting oral (LAO) therapies, for $30-mn advance in oral drug delivery in decades, (2020) to $13.1-mn (2021) to $10.7-mn
(Rs. 249-crore). No more details were creating medicines that last for a week (2022).
Delhi HC asks Natco Pharma to pause Risdiplam

launch amid patent dispute

The division bench of the Delhi Swiss multinational F. Hoffmann-La Roche had sought an interim in-
High Court on March 26 has asked Roche had appealed against a single junction against Natco Pharma to res-
Natco Pharma to maintain status quo judge order delivered on March 24 that train infringement of its patent titled
on the launch of its drug Risdiplam till had refused to stop Natco Pharma from ‘compounds for treating spinal mus-
April 2. Risdiplam is an oral medicine manufacturing Risdiplam in India for cular atrophy’. It alleged that Natco
for spinal muscular atrophy in patients the rare disease. Pharma was planning to commercially
two months of age or older. manufacture Risdiplam and this would
Roche has a registered patent, which is infringe its patent for Risdiplam that
A Division Bench led by Justice a “species patent” for Risdiplam, an active will expire in May 2035. The Swiss
Hari Shankar asked Hyderabad-based pharmaceutical ingredient in the Swiss company had said that Natco Pharma’s
generic drug manufacturer to hold on fi rm’s commercial product marketed motive was to only make profits
its hands till it heard the case on April 2. worldwide under the brand name Evrysdi. “by imitating” it.
Morepen Labs gets China approval for Loratadine API

Morepen Laboratories has received its position as a leading exporter six APIs to 82 countries, with its API
approval from the Centre for Drug of Loratadine in international exports valued at Rs. 650-crore. Com-
Evaluation (CDE) of China’s National markets. Loratadine is a prescribed menting on the expansion, Mr. Kushal
Medical Products Administration second-generation antihistamine and Suri, Director-Sales & Marketing,
(NMPA) for its anti-allergy API, Lorata- anti-allergy drug used to treat allergic Morepen Laboratories, said, “China
dine. symptoms such as hay fever and represents a vast growth opportunity,
chronic urticaria. and this expansion will allow us to meet
With an 80 perent market share in the increasing demand for high-quality
the US, Morepen aims to strengthen Currently, the company exports antihistamine and anti-allergy APIs.”

Chemical Weekly April 8, 2025 153

Contents Index to Advertisers Index to Products Advertised